secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001493152-23-006354
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics licenses Inspirevax intranasal adjuvant BDX301 for COVID-19 vaccine candidate NT-CoV2-1
--------------------------------------------------------------------------------

- Upfront fee $50K; milestones up to $5.3M including $2M on first US sale; tiered royalties 7% net sales (decreasing to 4%).
- Development milestones: first patient in clinical study by Dec 31, 2023; Phase 2a by Sep 30, 2024; Phase 3 by Dec 31, 2026; marketing app by Jun 30, 2028.
- Preclinical GLP toxicology study in rabbits showed no toxicity signals or adverse events for NT-CoV2-1 plus BDX301.
- Companies to form Joint Development Committee; option to expand collaboration to other intranasal vaccine candidates.
- Oragenics to provide program update in mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223006354/0001493152-23-006354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223006354/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer